search
Back to results

Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction (bTUNED)

Primary Purpose

Neurogenic Bladder Dysfunction

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Experimental TTNS
Sham TTNS
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neurogenic Bladder Dysfunction focused on measuring Randomized, Sham-controlled, Transcutaneous tibial nerve stimulation (TTNS), Neurogenic detrusor overactivity, Neuromodulation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed consent
  • Age >18 years
  • Last urethro-cystoscopy and bladder washing cytology within 1 year before inclusion
  • Last urodynamic investigation within 6 months and no change of bladder medication since then

  • Refractory LUTD due to a neurological disorder:

    1. Neurogenic OAB (i.e. urgency frequency syndrome with or without urgency incontinence) refractory to antimuscarinics (pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics)
    2. Neurogenic voiding dysfunction (i.e. incomplete bladder emptying/incomplete / complete urinary retention) refractory to alpha-blocker (pharmacotherapy with an alpha-blocker for at least 4 weeks)
    3. Combination of neurogenic OAB and neurogenic voiding dysfunction (i.e. urgency frequency syndrome with or without urgency incontinence and incomplete / complete urinary retention) refractory to antimuscarinics (pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics) and alpha-blocker (pharmacotherapy with an alpha- blocker for at least 4 weeks)
  • Motor response induced by TTNS stimulation at least at one leg
  • Willing not to change or start any new medications or treatments for the LUT during the entire study period (from screening till unblinding)

Exclusion Criteria:

  • Contraindications to the investigational product
  • Known or suspected non-adherence, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia
  • Participation in another study with investigational drug or product within the 30 days preceding and during the present study
  • Neuromodulation treatment for urological indication in the last six months or ongoing
  • Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the study
  • Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html]
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Sites / Locations

  • University Hospital Antwerp
  • University of Sao Paulo School of Medicine
  • Careggi University Hospital
  • Tor Vergata University Hospital
  • Cantonal Hospital AarauRecruiting
  • REHAB Basel
  • EOC - Regional Hospital Bellinzona and Valleys
  • Centre hospitalier universitaire vaudois CHUV
  • Cantonal Hospital St. GallenRecruiting
  • Balgrist University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Transcutaneous tibial nerve stimulation (TTNS)

TTNS sham stimulation

Arm Description

Outcomes

Primary Outcome Measures

Success of TTNS
Success of TTNS defined as: ≥50% reduction in incontinence rates per 24 hours and/or ≥50% reduction in micturition/catheterization frequency per 24 hours in patients with neurogenic overactive bladder (OAB) Reduction of post void residual (PVR) below 25% of bladder capacity if bladder capacity 100 mL, or below 50% of bladder capacity if bladder capacity <100 mL in patients with neurogenic voiding dysfunction In patients with combined neurogenic OAB and neurogenic voiding dysfunction: The success criteria of leading symptom/dysfunction will be chosen

Secondary Outcome Measures

Volumetric changes during urodynamics and their relation to clinical outcomes
Cystometric capacity [mL], volume at first DO [mL], voided volume [mL] and post void residual [mL] as assessed by urodynamic measurement
Changes in bladder compliance [mL/cmH2O] during urodynamics and their relation to clinical outcomes
Pressure changes during urodynamics and their relation to clinical outcomes
Maximum DO pressure [cmH2O], detrusor leak-point pressure [cmH2O], maximum detrusor pressure [cmH2O] during storage phase, maximum detrusor pressure [cmH2O] during voiding phase, detrusor pressure at maximum flow rate [cmH2O] as assessed by urodynamic measurement
Changes in maximum flow rate [mL/s] as assessed by urodynamics and their relation to clinical outcomes
Changes in vesicoureterorenal reflux (VUR) as assessed by videography during urodynamics and their relation to clinical outcomes
Changes in pelvic floor activity as assessed by electromyography (EMG) during urodynamics and their relation to clinical outcomes
Changes in bladder storage and voiding parameters and their relation to clinical outcomes
Assessed by a bladder diary
Changes in bowel diary parameters and their relation to clinical outcomes
Assessed by a bowel diary
Goal attainment scaling assessed by a self-assessment goal achievement (SAGA) questionnaire
The baseline SAGA module asks patients to rate the importance of 9 prespecified (fixed) treatment goals that describe reducing the following LUTS: frequency (daytime and nighttime); sensation of pressure; primary sensation to use the bathroom; bladder voiding; starting or maintaining a urine stream; urine loss when coughing, laughing, exercising, or sneezing; urine leakage; and urgency. In addition to the 9 fixed goals, patients can list up to 5 additional (open) treatment goals. Patients rate the importance of each goal using a 5-point scale ranging from "not very important goal" to "very important goal." In the SAGA follow-up module, patients rate their achievement of each individualized goal and overall goal achievement with a 5-point scale ranging from "did not achieve goal" to "greatly exceeded goal."
Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes
The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."
Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes
The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).
Changes in Qualiveen questionnaire scores and their relation to clinical outcomes
Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).
Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes
The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).
Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes
The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.
Variability and validity of University of South Australia Urinary Symptom Assessment questionnaire (USA2) for treatment follow-up
The USA2 ("University of South Australia Urinary Symptom Assessment") assesses multiple dimensions of urgency sensation. 10 items are rated on a 6-point Likert-type scale from 0 to 5. Lower scores are reflecting lesser urgency symptoms. Domain scores are computed by summing the sores for individual items in each domain.
Changes in Neurogenic Bowel Dysfunction (NBD) questionnaire and their relation to clinical outcomes
The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).
Changes in neurophysiology measurements of evoked potentials (EPs) as well as nerve conduction measurements and their relation to clinical outcomes
Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes
Initial sensation [mL], volume at urge to defecate [mL], maximum tolerated volume [mL] as assessed by rectal sensitivity testing; rectal capacity [mL] assessed by barostat assessment
Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes
Basal Internal anal sphincter pressure [mmHg], squeeze external anal sphincter pressure [mmHg], relaxation internal anal sphincter pressure during defecation [mmHg], intraabdominal pressure during defecation [mmHg]
Changes in rectal compliance [mL/cmH2O] during anorectal manometry and barostat assessment and their relation to clinical outcomes
Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes
Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types manometric patterns (I-IV) that are identified through manometric assessments.
Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of AEs and SAE
Categories: infection - Urinary Tract Infection (UTI) infection - other than UTI skin irritation at the electrode site pressure ulcer severe neurological deterioration severe or sudden increase in pain severe or sudden increase in spasticity deep vein thrombosis / pulmonary embolism autonomic dysreflexia urgent (unexpected) transfer/admittance to an acute care facility

Full Information

First Posted
March 9, 2020
Last Updated
August 28, 2023
Sponsor
University of Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT04315142
Brief Title
Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction
Acronym
bTUNED
Official Title
Transcutaneous Tibial Nerve Stimulation (TTNS) for Treating Neurogenic Lower Urinary Tract Dysfunction: A Multicentre, Randomised, Sham-controlled, Double-blind Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2020 (Actual)
Primary Completion Date
August 2026 (Anticipated)
Study Completion Date
August 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Many patients with neurological diseases suffer from neurogenic lower urinary tract dysfunction (NLUTD), which often severely impairs quality of life, due to urinary urgency with or without incontinence and voiding dysfunction. In addition, the upper urinary tract may be jeopardized because of high intravesical pressure caused by detrusor overactivity (DO) with concurrent detrusor-sphincter-dyssynergia and/or low bladder compliance. The treatment of NLUTD is a challenge since conventional conservative therapies often fail and more invasive treatments such as intradetrusor onabotulinumtoxinA injections, bladder augmentation and urinary diversion have to be considered. Neuromodulation therapies including tibial nerve stimulation (TNS) may be alternative non-invasive treatment options. Indeed, TNS is an effective and safe treatment for idiopathic overactive bladder proven in randomised controlled trials (RCTs), but its value in neurological patients is unclear. In a recent systematic review, the investigators found evidence that TNS might become a promising treatment option for NLUTD, however, more reliable data from well-designed RCTs are urgently needed to reach definitive conclusions. However, this study will be the first adequately sampled and powered, randomised, sham-controlled, double-blind trial assessing transcutaneous TNS (TTNS) for NLUTD. It will provide significant insights into the efficacy of TTNS in patients suffering from NLUTD and in the case that this treatment is really effective in the neurological population, the investigators findings would completely revolutionize the management of NLUTD in daily clinical practice. Moreover, this interdisciplinary clinical trial will relevantly influence the neurological and urological approach in the management of NLUTD promoting future collaborative projects improving patients' medical care and underlying the pioneering role of Switzerland in the rapidly developing and ambitious research field of neuro-urology.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurogenic Bladder Dysfunction
Keywords
Randomized, Sham-controlled, Transcutaneous tibial nerve stimulation (TTNS), Neurogenic detrusor overactivity, Neuromodulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transcutaneous tibial nerve stimulation (TTNS)
Arm Type
Experimental
Arm Title
TTNS sham stimulation
Arm Type
Sham Comparator
Intervention Type
Device
Intervention Name(s)
Experimental TTNS
Intervention Description
30-minute TTNS intervention is performed 2 days a week during a treatment period of 6 weeks
Intervention Type
Device
Intervention Name(s)
Sham TTNS
Intervention Description
30-minute sham intervention is performed 2 days a week during a treatment period of 6 weeks
Primary Outcome Measure Information:
Title
Success of TTNS
Description
Success of TTNS defined as: ≥50% reduction in incontinence rates per 24 hours and/or ≥50% reduction in micturition/catheterization frequency per 24 hours in patients with neurogenic overactive bladder (OAB) Reduction of post void residual (PVR) below 25% of bladder capacity if bladder capacity 100 mL, or below 50% of bladder capacity if bladder capacity <100 mL in patients with neurogenic voiding dysfunction In patients with combined neurogenic OAB and neurogenic voiding dysfunction: The success criteria of leading symptom/dysfunction will be chosen
Time Frame
study week 8 / study end
Secondary Outcome Measure Information:
Title
Volumetric changes during urodynamics and their relation to clinical outcomes
Description
Cystometric capacity [mL], volume at first DO [mL], voided volume [mL] and post void residual [mL] as assessed by urodynamic measurement
Time Frame
Baseline; study week 8 / study end
Title
Changes in bladder compliance [mL/cmH2O] during urodynamics and their relation to clinical outcomes
Time Frame
Baseline; study week 8 / study end
Title
Pressure changes during urodynamics and their relation to clinical outcomes
Description
Maximum DO pressure [cmH2O], detrusor leak-point pressure [cmH2O], maximum detrusor pressure [cmH2O] during storage phase, maximum detrusor pressure [cmH2O] during voiding phase, detrusor pressure at maximum flow rate [cmH2O] as assessed by urodynamic measurement
Time Frame
Baseline; study week 1-8 / study end
Title
Changes in maximum flow rate [mL/s] as assessed by urodynamics and their relation to clinical outcomes
Time Frame
Baseline; study week 8 / study end
Title
Changes in vesicoureterorenal reflux (VUR) as assessed by videography during urodynamics and their relation to clinical outcomes
Time Frame
Baseline; study week 8 / study end
Title
Changes in pelvic floor activity as assessed by electromyography (EMG) during urodynamics and their relation to clinical outcomes
Time Frame
Baseline; study week 8 / study end
Title
Changes in bladder storage and voiding parameters and their relation to clinical outcomes
Description
Assessed by a bladder diary
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in bowel diary parameters and their relation to clinical outcomes
Description
Assessed by a bowel diary
Time Frame
Baseline; study week 8 / study end
Title
Goal attainment scaling assessed by a self-assessment goal achievement (SAGA) questionnaire
Description
The baseline SAGA module asks patients to rate the importance of 9 prespecified (fixed) treatment goals that describe reducing the following LUTS: frequency (daytime and nighttime); sensation of pressure; primary sensation to use the bathroom; bladder voiding; starting or maintaining a urine stream; urine loss when coughing, laughing, exercising, or sneezing; urine leakage; and urgency. In addition to the 9 fixed goals, patients can list up to 5 additional (open) treatment goals. Patients rate the importance of each goal using a 5-point scale ranging from "not very important goal" to "very important goal." In the SAGA follow-up module, patients rate their achievement of each individualized goal and overall goal achievement with a 5-point scale ranging from "did not achieve goal" to "greatly exceeded goal."
Time Frame
Baseline; study week 8 / study end
Title
Changes in International Prostate Symptom (IPSS) questionnaire and their relation to clinical outcomes
Description
The IPSS ("International Prostate Symptom Questionnaire") score is based on questions concerning urinary symptoms and quality of life (QoL). It consists of 8 items covering 7 urinary symptoms related dimensions (subscales) and 1 additional item assessing quality of life. Each item is rated on a 6-point scale (0=not at all; 5=almost always). The lowest possible score in the total IPSS score is 0 (asymptomatic); the highest possible score is 35 (symptomatic). The QoL index is rated on a 7-point scale, with 0 indicating "delighted" and 6 "terrible."
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in urinary symptoms as assessed by the Urinary Symptom Profile (USP) questionnaire and their relation to clinical outcomes
Description
The USP ("Urinary Symptom Profile") score is based on questions concerning urinary symptoms and their severity in males and females. It consists of 13 items covering 3 dimensions (subscales) with 7 overactive bladder (OAB), 3 stress urinary incontinence (SUI), and 3 low stream (LS) related items. Each item is rated on a 4-point scale. The lowest score is 0 (asymptomatic); the highest score is 3 (symptomatic).
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in Qualiveen questionnaire scores and their relation to clinical outcomes
Description
Qualiveen-30 assesses the Specific Impact of Urinary Problems (SIUP) on Quality of Life. It consists of 30 items covering 4 domains, namely inconvenience (9 questions), restrictions (8 questions), fears (8 questions), and impact on daily life (5 questions). Each item is rated on a 5-point ordinal scale (0=asymptomatic; 4=symptomatic). The index of the SIUP on Quality of Life is the mean of the four individual scores. The lowest possible overall score in the Qualiveen-30 is 0 (Urinary problems have no specific impact on QoL); the highest possible score is 30 (Urinary problems have a huge specific impact on QoL).
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in Female Sexual Function Index (FSFI) and their relation to clinical outcomes
Description
The FSFI ("Female Sexual Function Index") is based on questions concerning female sexual functions. It consists of 19 items covering 6 domains, namely sexual desire, arousal (both subjective and physiologic), lubrication, orgasm, satisfaction, and pain. The lowest possible score in the total FSFI is 2 (asymptomatic); the highest possible score is 36 (symptomatic).
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in International Index of Erectile Function (IIEF) and their relation to clinical outcomes
Description
The IIEF ("International Index of Erectile Function") is based on questions concerning erectile dysfunction. It consists of 15 items covering 5 domains, namely erectile functioning, orgasmic functioning, sexual desire, and intercourse satisfaction along with a fifth component which encompasses the concept of overall sexual satisfaction. While items 1-10 are rated on a 6-point Likert-type scale from 0 to 5, items 11-15 are rated on a 5-point Likert-type scale from 1 to 5. Higher scores are reflecting less dysfunction. Domain scores are computed by summing the sores for individual items in each domain.
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Variability and validity of University of South Australia Urinary Symptom Assessment questionnaire (USA2) for treatment follow-up
Description
The USA2 ("University of South Australia Urinary Symptom Assessment") assesses multiple dimensions of urgency sensation. 10 items are rated on a 6-point Likert-type scale from 0 to 5. Lower scores are reflecting lesser urgency symptoms. Domain scores are computed by summing the sores for individual items in each domain.
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in Neurogenic Bowel Dysfunction (NBD) questionnaire and their relation to clinical outcomes
Description
The NBD ("Neurogenic Bowel Dysfunction") score is based on questions concerning constipation and fecal incontinence and was developed for and validated in the spinal cord injury population. It consists of 10 items. The lowest possible score in the total NBD is 0 (asymptomatic); the highest possible score is 47 (symptomatic). The interpretation of the total NBD score is very minor NBD (0-6), minor NBD (7-9), moderate NBD (10-13), and severe NBD (≥14).
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Changes in neurophysiology measurements of evoked potentials (EPs) as well as nerve conduction measurements and their relation to clinical outcomes
Time Frame
Baseline; once per week during the TTNS intervention period; study week 8 / study end
Title
Volumetric changes during rectal sensitivity testing and barostat assessment and their relation to clinical outcomes
Description
Initial sensation [mL], volume at urge to defecate [mL], maximum tolerated volume [mL] as assessed by rectal sensitivity testing; rectal capacity [mL] assessed by barostat assessment
Time Frame
Baseline; study week 8 / study end
Title
Pressure changes during anorectal manometry and barostat assessment and their relation to clinical outcomes
Description
Basal Internal anal sphincter pressure [mmHg], squeeze external anal sphincter pressure [mmHg], relaxation internal anal sphincter pressure during defecation [mmHg], intraabdominal pressure during defecation [mmHg]
Time Frame
Baseline; study week 8 / study end
Title
Changes in rectal compliance [mL/cmH2O] during anorectal manometry and barostat assessment and their relation to clinical outcomes
Time Frame
Baseline; study week 8 / study end
Title
Changes in defecatory disorder [Rao's classification] identified during anorectal manometry and their relation to clinical outcomes
Description
Anorectal manometry is the preferable test for defecatory disorder. Rao's classification describes the four types manometric patterns (I-IV) that are identified through manometric assessments.
Time Frame
Baseline; study week 8 / study end
Title
Incidence of side effects as well as number and intensity/severity (mild/moderate/severe) of AEs and SAE
Description
Categories: infection - Urinary Tract Infection (UTI) infection - other than UTI skin irritation at the electrode site pressure ulcer severe neurological deterioration severe or sudden increase in pain severe or sudden increase in spasticity deep vein thrombosis / pulmonary embolism autonomic dysreflexia urgent (unexpected) transfer/admittance to an acute care facility
Time Frame
During complete study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed consent Age >18 years Last urethro-cystoscopy and bladder washing cytology within 1 year before inclusion Last urodynamic investigation within 6 months and no change of bladder medication since then Refractory LUTD due to a neurological disorder: Neurogenic OAB (i.e. urgency frequency syndrome with or without urgency incontinence) refractory to antimuscarinics (pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics) Neurogenic voiding dysfunction (i.e. incomplete bladder emptying/incomplete / complete urinary retention) refractory to alpha-blocker (pharmacotherapy with an alpha-blocker for at least 4 weeks) Combination of neurogenic OAB and neurogenic voiding dysfunction (i.e. urgency frequency syndrome with or without urgency incontinence and incomplete / complete urinary retention) refractory to antimuscarinics (pharmacotherapy for at least 4 weeks with at least 2 antimuscarinics) and alpha-blocker (pharmacotherapy with an alpha- blocker for at least 4 weeks) Motor response induced by TTNS stimulation at least at one leg Willing not to change or start any new medications or treatments for the LUT during the entire study period (from screening till unblinding) Exclusion Criteria: Contraindications to the investigational product Known or suspected non-adherence, drug or alcohol abuse Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia Participation in another study with investigational drug or product within the 30 days preceding and during the present study Neuromodulation treatment for urological indication in the last six months or ongoing Botulinum toxin injections in the detrusor and/or urethral sphincter in the last six months Women who are pregnant or breast feeding Intention to become pregnant during the course of the study Individuals especially in need of protection (according to Research with Human Subjects published by the Swiss Academy of Medical Sciences [www.samw.ch/en/News/News.html] Enrolment of the investigator, his/her family members, employees and other dependent persons
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas M Kessler, Prof.
Phone
0041 44 386 39 07
Email
thomas.kessler@balgrist.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Oliver Gross, Dr.
Phone
0041 44 386 39 07
Email
oliverheinz.gross@balgrist.ch
Facility Information:
Facility Name
University Hospital Antwerp
City
Edegem
Country
Belgium
Individual Site Status
Suspended
Facility Name
University of Sao Paulo School of Medicine
City
São Paulo
Country
Brazil
Individual Site Status
Suspended
Facility Name
Careggi University Hospital
City
Florence
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Tor Vergata University Hospital
City
Rome
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Cantonal Hospital Aarau
City
Aarau
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maciej Kwiatkowski, PD Dr. med.
Email
maciej.kwiatkowski@ksa.ch
Facility Name
REHAB Basel
City
Basel
Country
Switzerland
Individual Site Status
Suspended
Facility Name
EOC - Regional Hospital Bellinzona and Valleys
City
Bellinzona
Country
Switzerland
Individual Site Status
Suspended
Facility Name
Centre hospitalier universitaire vaudois CHUV
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Cantonal Hospital St. Gallen
City
Sankt Gallen
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Engeler, PD Dr. med.
Email
daniel.engeler@kssg.ch
Facility Name
Balgrist University Hospital
City
Zürich
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas M Kessler, Prof.
Email
thomas.kessler@balgrist.ch
First Name & Middle Initial & Last Name & Degree
Oliver Gross, Dr. med.
Email
oliverheinz.gross@balgrist.ch

12. IPD Sharing Statement

Learn more about this trial

Bladder and TranscUtaneous Tibial Nerve Stimulation for nEurogenic Lower Urinary Tract Dysfunction

We'll reach out to this number within 24 hrs